NBS Present at Multiple Conferences in November NEW

New Post Public Reply Private Reply Replies (0) Message Board
Compensated Post
shakerzzz

[b]NBS >> Present at Multiple Conferences in November[/b]


NEW YORK, Oct. 31, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that Company management and management of its subsidiary, Progenitor Cell Therapy ("PCT"), have been invited to present at multiple conferences in November.

American Heart Association – Scientific Sessions 2012

Date: November 6, 2012, 11:00 AM PST
Venue: Los Angeles Convention Center, Los Angeles, CA
Session Title: Cardiovascular Regeneration: From Bench to Clinic
Presenter: Jonathan Sackner-Bernstein, M.D., FACC, Vice President, Clinical Development and Regulatory Affairs of NeoStem will present an abstract titled "Predictors of Response to Intracoronary Delivery of CD34+CXCR4+ Enriched Bone Marrow Derived Stem Cells (AMR-001) Early After STEMI"
2012 ISPE Annual Meeting: Global GMP Solutions through Innovation and Transformation

Date: November  12, 2012, 3:30 PM PST
Venue: Marriott Marquis, San Francisco, CA
Presenter: Sanjin Zvonic, Ph.D., Director of Technology and Business Development of PCT, will speak on "Immunotherapies and Tissue Culture Manufacturing Technologies" within the Biotechnology Executive Series Session
Lazard Capital Markets 9th Annual Healthcare Conference

Date: November 14, 2012, 10:00 AM EST
Venue: The Pierre Hotel, New York, NY
Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem will give a company presentation.
New York Society of Security Analysts' 16th Annual "Investing in Life Sciences" Conference

Date: November 29, 2012, 11:15 AM EST
Venue: NYSSA Conference Center, New York, NY
Presenters: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem will give a company presentation.
About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information, please visit www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing ("CDMO") business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 7

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
Davos Healthcare Aims to Revolutionize Hospital Ratings

Updated Category News Views 6

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Continue Reading
AI-Driven Lumi Transforms Car Dealership Interactions

Updated Category News Views 7

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Continue Reading
Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Updated Category News Views 4

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

Continue Reading
FJBio Boosts Antibody Discovery with Sapio AI

Updated Category News Views 5

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Continue Reading
Cracking the Code of America's Delivery Addiction

Updated Category News Views 4

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Continue Reading
Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 5

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 6

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 5

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
FutureVault's AI Agents: Transforming Financial Workflows

Updated Category News Views 4

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Continue Reading

Top 5 Most Recently Viewed Articles

PMGC Capital's Strategic Investment in Alaunos Therapeutics

Updated Category News Views 171

PMGC Capital LLC Plans to File Schedule 13D on Alaunos PMGC Capital LLC, a fully owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), has made a significant move in the financial landscape by announcing its intention to file a Schedule 13D with the U.S. Securities and Exchange Commission (SEC). This filing will disclose its beneficial ownership in Alaunos Therapeutics,...

Continue Reading
Black Diamond Therapeutics: Pivotal Developments Ahead

Updated Category News Views 97

Black Diamond Therapeutics Continues to Make Strides Recently, H.C. Wainwright confirmed a Buy rating on Black Diamond Therapeutics (NASDAQ: BDTX) shares, projecting a price target of $11.00. This positive outlook follows the company's major restructuring efforts aimed at advancing BDTX-1535, its leading drug candidate, into pivotal trials. This move is expected to not...

Continue Reading
Eureka Acquisition Corp Announces New Meeting Date and Deadlines

Updated Category News Views 187

Eureka Acquisition Corp's Important Announcement New York — Eureka Acquisition Corp (NASDAQ: EURK), a special purpose acquisition company, has recently made significant announcements regarding the schedule of its extraordinary general meeting. Originally set for June 20, it will now take place on June 25, providing shareholders with extra time for participation. Details...

Continue Reading
Diamedica Therapeutics Hits New Heights with $6.41 Stock Value

Updated Category News Views 118

Diamedica Therapeutics Inc. Achieves 52-Week High Diamedica Therapeutics Inc. (NASDAQ: DMAC) is making headlines as its stock has recently hit a remarkable 52-week high of $6.41. This impressive milestone comes amid a significant growth phase for the company, which is currently valued at around $230 million. The steep rise in the stock price over the past year indicates a...

Continue Reading
J.P. Morgan's Projections for 2025: Capital Market Insights

Updated Category News Views 6083

J.P. Morgan's Capital Market Assumptions for 2025 J.P. Morgan Asset Management has recently unveiled its 2025 Long-Term Capital Market Assumptions (LTCMAs), providing valuable insights into the anticipated returns and risks across various asset classes for the next decade. These projections serve as a compass for investment strategies, targeting institutional and...

Continue Reading